Skip to main content
Fig. 2 | Eye and Vision

Fig. 2

From: Wide-field swept-source OCT angiography of the periarterial capillary-free zone before and after anti-VEGF therapy for branch retinal vein occlusion

Fig. 2

Representative swept-source optical coherence tomography angiography (SS-OCTA) images and measurements of the periarterial capillary-free zone (paCFZ) areas and corresponding artery areas, including calculation of the paCFZ/artery (P/A) ratios in a patient with branch retinal vein occlusion (BRVO). The patient’s best-corrected visual acuity of the affected eye was 60 letters at baseline and 75 letters at 12 months after intravitreal ranibizumab therapy. ac SS-OCTA images of the healthy contralateral eye (a), the BRVO eye at baseline (b), and the BRVO eye at 12 months after ranibizumab therapy (c). The details of the paCFZ areas along the first- and second-order arteries were shown in the magnified squares. d–f Measurements of the paCFZ areas and corresponding artery areas shown in a (d), b (e) and c (f). The magnified squares demonstrated the detailed measurement of paCFZ and artery areas. gi The corresponding 12 × 12 mm B-scan images of the superficial capillary plexus. a The first- and second-order arteries in the inferotemporal quadrant were determined in the healthy contralateral eye. d For measurements of the first- and second-order arteries in the healthy contralateral eye, the paCFZ areas were 0.50 mm2 and 0.44 mm2, respectively, the artery areas were 0.60 mm2 and 0.33 mm2, respectively, and the P/A ratios were 0.83 and 1.33, respectively. The details of the paCFZ areas along the first- and second-order arteries were shown in the magnified squares. b The BRVO eye exhibited retinal nonperfusion in the affected supertemporal quadrant of the retina. e For the first- and second-order arteries in the inferotemporal quadrant, the paCFZ areas were 0.60 mm2 and 1.14 mm2, respectively, the artery areas were 0.56 mm2 and 0.68 mm2, respectively, and the P/A ratios were 1.07 and 1.68, respectively. c, f For measurements of the first- and second-order arteries at 12 months after ranibizumab therapy, the paCFZ areas were 0.48 mm2 and 0.78 mm2, respectively, the artery areas were 0.57 mm2 and 0.58 mm2, respectively, and the P/A ratios were 0.84 and 1.34, respectively. The paCFZ areas and P/A ratios were greater in the affected eye than in the healthy contralateral eye at baseline, but these parameters decreased with a reduction in macular edema after five intravitreal injections of ranibizumab

Back to article page